首页> 外国专利> PREPARATION OF NON-CRYSTALLINE ATORVASTATIN CALCIUM

PREPARATION OF NON-CRYSTALLINE ATORVASTATIN CALCIUM

机译:非晶体阿托伐他汀钙的制备

摘要

Atorvastatin, a substance with the chemical name hemi calcium salt of (R-(R*,R*))-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1 methylethyl)-3-phenyl-4((enylamino)carbonyl)-1H-pyrrol-1-heptanoic acid, is known as the inhibitor of HMG-CoA reductase and has been used as an antihypercholesterolemic. Atorvastatin has been always prepared in the form of a calcium salt convenient for preparation of suitable pharmaceutical formulations such as pills, capsules, powders and other forms appropriate for oral administration. It can exist in the amorphous as well as one of the four crystalline forms (Form I, II, III, and IV). Atorvastatin is a very low water-soluble substance, but it has been found out that its crystalline forms are lower soluble than the amorphous one, a fact that may influence its bioavailability in the body. The submitted invention refers to a new procedure of direct transformation of an intermediate in the synthesis of atorvastatin 44a or 44 or atorvastatin lactone into the amorphous atorvastatin.
机译:阿托伐他汀,一种化学名称为(R-(R *,R *))-2-(4-氟苯基)-β,δ-二羟基-5-(1甲基乙基)-3-苯基-4的半钙盐的物质((烯氨基)羰基)-1H-吡咯-1-庚酸已知是HMG-CoA还原酶的抑制剂,并已被用作抗高胆固醇血症药物。阿托伐他汀一直以钙盐的形式制备,方便于制备合适的药物制剂,例如丸剂,胶囊剂,散剂和其他适合口服的形式。它可以以无定形形式以及四种结晶形式(形式I,II,III和IV)之一存在。阿托伐他汀是一种非常低的水溶性物质,但已发现其结晶形式的溶解度低于无定形物质,这可能会影响其在体内的生物利用度。提交的发明涉及将阿托伐他汀44a或44或阿托伐他汀内酯的合成中的中间体直接转化为无定形阿托伐他汀的新方法。

著录项

  • 公开/公告号HRP20030575B1

    专利类型

  • 公开/公告日2011-10-31

    原文格式PDF

  • 申请/专利权人 LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D.;

    申请/专利号HR2003P000575

  • 发明设计人 GORAZD SORSAK;

    申请日2003-07-15

  • 分类号C07D207/34;A61P3;A61P7;C07D405/06;

  • 国家 HR

  • 入库时间 2022-08-21 18:06:33

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号